US Transdermal Patch Market Has Bright Future, States Kuick Research in New Report Now Available at MarketPublishers.com25 Jul 2016 • by Natalie Aster
LONDON – The transdermal product market has gathered rapid momentum since its innovation and is likely to continue for the foreseeable future. A rising number of transdermal drug delivery (TDD) products keep on delivering substantial therapeutic benefit to patients from pole to pole. A total of 32 transdermal products have received FDA approval over the last 2 decades, with most of them using passive transport that enables the drug to be constantly absorbed into the skin through natural processes.
In the USA, innovative technologies pertaining to transdermal patches have been introduced for the various indications for which no transdermal product was available enabling them to grab the large slices of the market pie. A hike in the demand for improved therapeutics at acceptable prices is anticipated to be the key driver of the growth of the country’s marketplace. Advances in material science, improved production capabilities and high acceptance rates are anticipated to give a boost to the segment. Meantime, some currently central issues such as lesser coverage of indications have yet to be dealt with in the offing. Another issue pertains to technology and needs to be enhanced to a greater degree to to come forth with HIV infection. At large, the US transdermal patch market will likely to gather steam mirroring a bright future.
New cutting-edge report “US Transdermal Patch Market Outlook 2020” created by Kuick Research examines the market on a country level. The research publication offers product classification; covers transdermal patch drug delivery; casts light on the generic and branded transdermal patches; contains a value chain analysis for the US transdermal patch marketplace; gives information on the respective contract manufacturing organisation. Furthermore, the study provides detailed insights into the US transdermal patch clinical pipeline based on indication, company and by phase; covering 55 patches in development, 23 patches in preclinical phase, marketed transdermal patches by firm and indication as well as 32 transdermal patches marketed in USA. The report provides an analysis of the competitive landscape and profiles 38 market players. An assessment of the major drivers and challenges in the market is provided, too.
More new studies by the publisher can be found at Kuick Research page.